Half-year report · Q2
4671.TEDINET S100UP43
Period2024-04-01 → 2024-09-30
Filed2024-11-12
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥21.4bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Revenue | ¥43.0bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥21.3bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Operating income | ¥974m | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Operating income | ¥851m | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Ordinary income | ¥1.0bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥2.3bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥931m | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥1.2bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥1.1bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥794m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.7bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥629m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥794m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Net income | ¥629m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Total assets | ¥36.2bn | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥36.4bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥36.7bn | at 2023-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥10.2bn | at 2024-09-30 | Cons. | Liabilities |
| Total liabilities | ¥10.4bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥25.9bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥26.0bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥26.0bn | at 2023-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥10.6bn | at 2024-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥10.1bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥10.6bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥10.1bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥9.2bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥12.6bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥1.4bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥3.4bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.7bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥73m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.4bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.9bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥860m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥4.5bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥3.2bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥74.46 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥151.72 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥56.29 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥74.25 | 2024-04-01 → 2024-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥150.9 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥56.14 | 2023-04-01 → 2023-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 71.4% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 71.2% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.6% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 36
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | ¥0 |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥0 |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥176m |
| jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥13.1bn |
| jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥13.1bn |
| jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥0 |
| jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥726m |
| jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥7.7bn |
| jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥7.7bn |
| jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥0 |
| jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥347m |
| jpcrp040300-q2r_E04982-000ICT Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥538m |
| jpcrp040300-q2r_E04982-000ICT Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥538m |
| jpcrp040300-q2r_E04982-000ICT Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥76m |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥21.4bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥21.4bn |
| —segment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥0 |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥1.1bn |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | ¥0 |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥0 |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥270m |
| jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥13.0bn |
| jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥13.0bn |
| jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥0 |
| jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥689m |
| jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥7.9bn |
| jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥7.9bn |
| jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥0 |
| jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥385m |
| jpcrp040300-q2r_E04982-000ICT Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥449m |
| jpcrp040300-q2r_E04982-000ICT Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥449m |
| jpcrp040300-q2r_E04982-000ICT Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥46m |
| —segment total | revenue | 2023-04-01 → 2023-09-30 | ¥21.3bn |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥21.3bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥0 |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | ¥1.1bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 522
| Item | Context | Value | Unit |
|---|---|---|---|
| Provision for bonuses sga | Prior1YTDDuration | 218000000 | JPY |
| Provision for bonuses sga | CurrentYTDDuration | 204000000 | JPY |
| Retirement benefit expenses sga | Prior1YTDDuration | 76000000 | JPY |
| Retirement benefit expenses sga | CurrentYTDDuration | 61000000 | JPY |
| Welfare expenses sga | Prior1YTDDuration | 499000000 | JPY |
| Welfare expenses sga | CurrentYTDDuration | 495000000 | JPY |
| Depreciation sga | Prior1YTDDuration | 97000000 | JPY |
| Depreciation sga | CurrentYTDDuration | 77000000 | JPY |
| Rent expenses sga | Prior1YTDDuration | 270000000 | JPY |
| Rent expenses sga | CurrentYTDDuration | 260000000 | JPY |
| Supplies expenses sga | Prior1YTDDuration | 494000000 | JPY |
| Supplies expenses sga | CurrentYTDDuration | 558000000 | JPY |
| Amortization of goodwill sga | Prior1YTDDuration | 8000000 | JPY |
| Amortization of goodwill sga | CurrentYTDDuration | 2000000 | JPY |
| Miscellaneous expenses sga | Prior1YTDDuration | 150000000 | JPY |
| Miscellaneous expenses sga | CurrentYTDDuration | 181000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E04982-000ClinicalTestingBusinessReportableSegmentsMember | 12971000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E04982-000DispensingPharmacyBusinessReportableSegmentsMember | 7904000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E04982-000ICTBusinessReportableSegmentsMember | 449000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReportableSegmentsMember | 21325000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 21325000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E04982-000ClinicalTestingBusinessReportableSegmentsMember | 0 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E04982-000DispensingPharmacyBusinessReportableSegmentsMember | 0 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E04982-000ICTBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_ReportableSegmentsMember | 0 | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | -0 | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E04982-000ClinicalTestingBusinessReportableSegmentsMember | 12971000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E04982-000DispensingPharmacyBusinessReportableSegmentsMember | 7905000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E04982-000ICTBusinessReportableSegmentsMember | 449000000 | JPY |
| Net sales | Prior1YTDDuration_ReportableSegmentsMember | 21326000000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | -0 | JPY |
| Net sales | Prior1YTDDuration | 21325000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E04982-000ClinicalTestingBusinessReportableSegmentsMember | 689000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E04982-000DispensingPharmacyBusinessReportableSegmentsMember | 385000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E04982-000ICTBusinessReportableSegmentsMember | 46000000 | JPY |
| Operating income | Prior1YTDDuration_ReportableSegmentsMember | 1121000000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | -270000000 | JPY |
| Operating income | Prior1YTDDuration | 851000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E04982-000ClinicalTestingBusinessReportableSegmentsMember | 13095000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E04982-000DispensingPharmacyBusinessReportableSegmentsMember | 7732000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E04982-000ICTBusinessReportableSegmentsMember | 538000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReportableSegmentsMember | 21366000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 21366000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E04982-000ClinicalTestingBusinessReportableSegmentsMember | 0 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E04982-000DispensingPharmacyBusinessReportableSegmentsMember | 0 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E04982-000ICTBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_ReportableSegmentsMember | 0 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |